Pharmacy Services Alerts
Losartan and Losartan-containing Products Recall – Raw Ingredient May Contain a Potential Carcinogen – UPDATED
Jan 24, 2019 10:00 AM
In November 2018, Sandoz Inc. voluntarily recalled tablets of losartan potassium co-formulated with hydrochlorothiazide. The recall affects 6 lots of losartan potassium – hydrochlorothiazide tablets distributed after October 8, 2018. One of the raw ingredients, losartan, USP, made by Zhejiang Huahai Pharmaceutical Co. contains the contaminant N-nitrosodiethylamine (NDEA). In December 2018 and January 2019, Torrent recalled 10 lots of losartan potassium 100 mg tablets. The raw ingredient, losartan, USP, made by Hetero Labs Limited, contains the contaminant NDEA. The International Agency for Research on Cancer classifies NDEA as a probable human carcinogen. It is found naturally occurring in certain foods, drinking water, air pollution, and industrial processes. No adverse events have been reported at this time.
Pharmacies should cease distribution of, and quarantine all affected products. Return the recalled product per the instructions of each individual supplier. Patients should continue taking their medication until they can contact their healthcare provider to discuss alternative options. Patients with questions or concerns about this recall can contact Sandoz Inc. at 800-525-8747 or by email at firstname.lastname@example.org; Torrent Pharmaceuticals by phone at 800-912-9561 or email at email@example.com. Consumers should report any adverse reactions from this product to their provider. Reactions may be reported to FDA through the MedWatch Adverse Event Reporting program at www.fda.gov/safety/medwatch/.
- Torrent Pharmaceuticals press release – January 22, 2019
- Torrent Pharmaceuticals press release – January 3, 2019
- Sandoz Inc. press release – November 8, 2018
- FDA updates on angiotensin II receptor blocker (ARB) recalls
- FDA Q&A on impurities found in ARB products